Multiple myeloma

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

Johnson & Johnson is restoring the true meaning of healthcare by developing advanced treatments and smarter and less invasive solutions for today’s most complex diseases.

In the quest to solve the toughest health challenges, innovating therapies and finding treatments are essential—but so is supporting the patients living with these diseases. That’s exactly why Johnson & Johnson launched HealtheVoices a decade ago.

What once seemed like an out-of-reach goal may soon be within our grasp. Learn how Johnson & Johnson is working toward its vision of helping create a world without cancer.

A treatment for an incurable cancer. Catheters to better diagnose and treat AFib. A surgical stapler that’s easier to use. These are just some of the Johnson & Johnson advances that are helping improve the health of people everywhere.

Johnson & Johnson has been dedicated to developing innovative treatments for blood cancers for nearly 20 years. Scientist Kodandaram “Ram” Pillarisetti is at the forefront of the company’s commitment to working toward its goal of one day eliminating the disease.

When Craig was diagnosed with multiple myeloma, his wife Cara took on a new role: caregiver. For National Caregiver’s Day, she shares the challenges—as well as the triumphs—of this difficult journey.

Mobilizing to help coworkers in need. Increasing diverse representation in clinical trials. Advocating on behalf of people living with life-altering medical conditions. Learn about the extraordinary ways these trailblazers made a difference in 2022.

For National Cancer Prevention Month, we’re spotlighting three leading Johnson & Johnson female hematologists—innovators who are not only saving lives and advancing new treatments but also paving the way for the next generation of women in their field.

Imagine having a disease that many doctors have never seen before. That’s what Marty Verel experienced when he was told he had AL amyloidosis—and it’s what hematologist Brendan Weiss, M.D., is determined to help change. For Rare Disease Day, Dr. Weiss shares what he’s learned studying the rare disease.